Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
1998-05-18
2001-08-14
Achutamurthy, Ponnathapu (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S006120, C435S320100, C435S325000, C536S023200
Reexamination Certificate
active
06274361
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, the invention relates to polynucleotides and polypeptides of the peptidyl-tRNA hydrolases family, as well as their variants, hereinafter referred to as “pth,” “pth polynucleotide(s),” and “pth polypeptide(s)” as the case may be
BACKGROUND OF THE INVENTION
It is particularly preferred to employ Staphylococcal genes and gene products as targets for the development of antibiotics. The Staphylococci make up a medically important genera of microbes. They are known to produce two types of disease, invasive and toxigenic. Invasive infections are characterized generally by abscess formation effecting both skin surfaces and deep tissues.
S. aureus
is the second leading cause of bacteremia in cancer patients. Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacterial endocarditis are also relatively common. There are at least three clinical conditions resulting from the toxigenic properties of Staphylococci. The manifestation of these diseases result from the actions of exotoxins as opposed to tissue invasion and bacteremia. These conditions include: Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome.
The frequency of
Staphylococcus aureus
infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate
Staphylococcus aureus
strains which are resistant to some or all of the standard antibiotics. This phenomenon has created an unmet medical need and demand for new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this organism.
Moreover, the drug discovery process is currently undergoing a fundamental revolution as it embraces “functional genomics,” that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on “positional cloning” and other methods. Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available as well as from other sources. There is a continuing and significant need to identify and characterize further genes and other polynucleotides sequences and their related polypeptides, as targets for drug discovery.
Clearly, there exists a need for polynucleotides and polypeptides, such as the pth embodiments of the invention, that have a present benefit of, among other things, being useful to screen compounds for antibiotic activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent, ameliorate or correct such infection, dysfunction and disease.
Peptidyl tRNA hydrolase plays a pivotal role in mRNA translation, regenerating tRNA from peptidyl tRNA intermediates. Pth activity is apparently ubiquitous and pth homologs have been identified in a wide range of bacteria. Analogous activity in mammals is mediated by a quite different set of enzymes. Inhibition of Pth activity in
E. coli
results in the inhibition of protein synthesis and ultimately cell death. We have shown that Pth is essential for in vitro growth in
S. pneumoniae
and
S. aureus
and that the gene encoding for this protein is expressed during infection of both pathogenic strains. Therefore, inhibitors of this protein could prevent the bacterium from establishing or maintaining infection of the host and thereby have utility in anti-bacterial therapy.
Certain of the polypeptides of the invention possess significant amino acid sequence homology to a known
B. subtilis
spoVC protein: Nearest polypeptide: Peptidyl-tRNA hydrolase (spoVC) (
B. subtilis
). Database: Swiss-Prot, accession number P37470; Ogasawara, N., Nakai, S. and Yoshikawa, H. Systematic sequencing of the 180 kilobase region of the
Bacillus subtilis
chromosome containing the replication origin; DNA Res. 1 (1), 1-14 (1994).
SUMMARY OF THE INVENTION
The present invention relates to pth, in particular pth polypeptides and pth polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of microbial diseases, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists using the materials provided by the invention, and for treating microbial infections and conditions associated with such infections with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with microbial infections and conditions associated with such infections, such as assays for detecting pth expression or activity.
Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.
DESCRIPTION OF THE INVENTION
The invention relates to pth polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a pth of
Staphylococcus aureus
, which is related by amino acid sequence homology to
B. subtilis
spoVC polypeptide. The invention relates especially to pth having the nucleotide and amino acid sequences set out in Table 1 as SEQ ID NO: 1 or 3 and SEQ ID NO: 2 or 4 respectively.
TABLE 1
pth Polynucleotide and Polypeptide Sequences
(A)
Staphylococcus aureus
pth polynucleotide sequence [SEQ ID NO:1].
5′-
ATGAAATGTATTGTAGGTCTAGGTAATATAGGTAAACGTTTTGAACTTACAAGACATAATATCGGCTTTGAA
GTCGTTGA
TTATATTTTAGAGAAAAATAATTTTTCATTAGATAAACAAAAGTTTAAAGGTGCATATACAATTGAACGAAT
GAACGGAG
ATAAAGTGTTATTTATCGAACCAATGACAATGATGAATTTGTCAGGAGAAGCAGTTGCACCGATTATGGATT
ATTACAAT
GTTAATCCAGAAGATTTAATTGTCTTATATGATGATTTAGATTTAGAACAAGGACAAGTTCGCTTAAGACAA
AAAGGAAG
TGCGGGCGGTCACAATGGTATGAAATCAATTATTAAAATGCTTGGTACAGACCAATTTAAACGTATTCGTAT
TGGTGTGG
GAAGACCAACGAATGGTATGACGGTACCTGATTATGTTTTACAACGCTTTTCAAATGATGAAATGGTAACGA
TGGAAAAA
GTTATCGAACACGCAGCACGCGCAATTGAAAAGTTTGTTGAAACATCACGATTTGACCATGTTATGAATGAA
TTTAATGG
TGAAGTGAAATAA-3′
(B)
Staphylococcus aureus
pth polypeptide sequence deduced from a
polynucleotide sequence in this table [SEQ ID NO:2].
NH
2
-
MKCIVGLGNIGKRFELTRHNIGFEVVDYILEKNNFSLDKQKFKGAYTIERMNGDKVLFIEPMTMMNLSGEAV
APIMDYYN
VNPEDLIVLYDDLDLEQGQVRLRQKGSAGGHNGMKSIIKMLGTDQFKRIRIGVGRPTNGMTVPDYVLQRFSN
DEMVTMEK
VIEHAARAIEKFVETSRFDHVMNEFNGEVK*-COOH
(C)
Staphylococcus aureus
pth ORF sequence [SEQ ID NO:3].
5′-
ATGAAATGTATTGTAGGTCTAGGTAATATAGGTAAACGTTTTGAACTTACAAGACATAATATCGGCTTTGAA
GTCGTTGA
TTATATTTTAGAGAAAAATAATTTTTCATTAGATAAACAAAAGTTTAAAGGTGCATATACAATTGAACGAAT
GAACGGAG
ATAAAGTGTTATTTATCGAACCAATGACAATGATGAATTTGTCAGGAGAAGCAGTTGCACCGATTATGGATT
ATTACAAT
GTTAATCCAGAAGATTTAATTGTCTTATATGATGATTTAGATTTAGAACAAGGACAAGTTCGCTTAAGACAA
AAAGGAAG
TGCGGGCGGTCACAATGGTATGAAATCAATTATTAAAATGCTTGGTACAGACCAATTTAAACGTATTCGTAT
TGGTGTGG
GAAGACCAACGAATGGTATGACGGTACCTGATTATGTTTTACAACGCTTTTCAAATGATGAAATGGTAACGA
TGGAAAAA
GTTATCGAACACGCAGCACGCGCAATTGAAAAGTTTGTTGAAACATCACGATTTGACCATGTTATGAATGAA
TTTAATGG
TGAAGTGAAATAA-3′
(D)
Staphylococcus aureus
pth polypeptide
Biswas Sanjoy
Burnham Martin K. R.
Fosberry Andrew P.
Hodgson John E
Lawlor Elizabeth J
Achutamurthy Ponnathapu
Deibert Thomas S.
Gimmi Edward R.
King William T.
SmithKline Beecham Corporation
LandOfFree
pth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with pth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and pth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2534787